# The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

> **NCT06140576** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 58 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Sindilimab
- **DRUG:** Nab-paclitaxel
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT06140576
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11-30
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2023-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06140576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06140576, "The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06140576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*